Patents by Inventor Edcon Chang

Edcon Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apoptosis signal-regulating kinase 1 inhibitors
    Patent number: 9403819
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: August 2, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Edcon Chang
  • Azaindole derivatives
    Patent number: 9371321
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: June 21, 2016
    Assignee: AstraZeneca AB
    Inventors: Edcon Chang, Christopher Smith, Xiaolun Wang, Michael B. Wallace
  • AZAINDOLE DERIVATIVES
    Publication number: 20150191465
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 9, 2015
    Inventors: Edcon Chang, Christopher Smith, Xiaolun Wang, Michael B. Wallace
  • N-substituted oxazinopteridines and oxazinopteridinones
    Patent number: 9045496
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: June 2, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • Apoptosis signal-regulating kinase 1 inhibitors
    Patent number: 8921358
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: December 30, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Matthew H. McNeill, Tracy Duong, Angie Vassar, Takehiro Hirano, Yoshito Terao
  • AZAINDOLE DERIVATIVES
    Publication number: 20140343033
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Applicant: Takeda Califomia, Inc.
    Inventors: Edcon Chang, Michael B. Wallace
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS
    Publication number: 20140329850
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventor: Edcon Chang
  • N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES
    Publication number: 20140309219
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • Azaindole derivatives
    Patent number: 8835420
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: September 16, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Wolfgang Reinhard Ludwig Notz, Michael B. Wallace
  • Apoptosis signal-regulating kinase 1 inhibitors
    Patent number: 8802695
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: August 12, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Edcon Chang
  • N-substituted oxazinopteridines and oxazinopteridinones
    Patent number: 8791107
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 29, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • AZAINDOLE DERIVATIVES
    Publication number: 20140018344
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3K?.
    Type: Application
    Filed: July 8, 2013
    Publication date: January 16, 2014
    Inventors: Edcon Chang, Wolfgang Reinhard Ludwig Notz, Michael B. Wallace
  • 5-membered heterocycle-based p38 kinase inhibitors
    Patent number: 8580838
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 12, 2013
    Assignee: Novartis AG
    Inventors: Hengyuan Lang, Olga M. Fryszman, Edcon Chang, Jiong Lan, Yunfeng Fang
  • Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
    Patent number: 8461163
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) . inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds, to methods and intermediates useful for making the compounds, and to methods of using the compounds.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Tracy Duong, Takehiro Hirano, Matthew H. McNiell, Yoshito Terao, Angie Vassar
  • 5-membered heterocycle-based P38 kinase inhibitors
    Patent number: 8410160
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS
    Publication number: 20120316194
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: January 21, 2011
    Publication date: December 13, 2012
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Edcon Chang
  • 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS
    Publication number: 20120264801
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Olga M. FRYSZMAN, Hengyuan LANG, Jiong LAN, Edcon CHANG, Yunfeng FANG
  • N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES
    Publication number: 20120220575
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R1, R2, R3, G1, G2, and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with PI3K?.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Edcon Chang, Tony Gibson, Bohan Jin, Nicholas Scorah, Qing Dong
  • 5-membered heterocycle-based p38 kinase inhibitors
    Patent number: 8242117
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
  • Apoptosis signal-regulating kinase 1 inhibitors
    Patent number: 8178555
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: May 15, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Stephen L. Gwaltney, Angie Vassar